Home > Oncology > ESMO 2022 > Fruquintinib: a potential new treatment option for patients with refractory mCRC

Fruquintinib: a potential new treatment option for patients with refractory mCRC

Presented By
Dr N. Arvind Dasari, MD Anderson Cancer Center, TX, USA
Conference
ESMO 2022
Trial
Phase 3, FRESCO-2
Results from the global, phase 3 FRESCO-2 trial demonstrate a doubling of progression-free survival (PFS) and almost a doubling of overall survival (OS) with the VEGF-1, -2, and -3 inhibitor fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (mCRC). The multi-TKI inhibitor regorafenib is standard-of-care in patients with (heavily) pre-treated, refractory mCRC [1]. The phase 3 FRESCO trial (NCT02314819) showed efficacy and safety of the VEGF-1, -2, and -3 inhibitor fruquintinib in Chinese patients with mCRC in a third (or later) line setting [2]. However, standard-of-care for mCRC in China differed from global patterns when FRESCO was conducted. For example, only 30% of participants in FRESCO had prior VEGF-inhibition and prior regorafenib was not allowed. To evaluate efficacy and safety of fruquintinib in a globally more represent...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on